Cargando…
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
BACKGROUND: Elbasvir (EBR) in combination with grazoprevir (GZR) has demonstrated efficacy in patients with hepatitis C virus (HCV) infections in trials primarily conducted in the USA and Europe. We investigated the safety and efficacy of EBR in combination with GZR in Japanese patients with chronic...
Autores principales: | Kumada, Hiromitsu, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Chayama, Kazuaki, Kawada, Norifumi, Okanoue, Takeshi, Itoh, Yoshito, Mochida, Satoshi, Toyoda, Hidenori, Yoshiji, Hitoshi, Takaki, Shintaro, Yatsuzuka, Naoyoshi, Yodoya, Etsuo, Iwasa, Takashi, Fujimoto, Go, Robertson, Michael N., Black, Stuart, Caro, Luzelena, Wahl, Janice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357479/ https://www.ncbi.nlm.nih.gov/pubmed/27873094 http://dx.doi.org/10.1007/s00535-016-1285-y |
Ejemplares similares
-
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
por: Chayama, Kazuaki, et al.
Publicado: (2017) -
Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study
por: Tateishi, Ryosuke, et al.
Publicado: (2014) -
Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021) -
Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021) -
Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)